MediPharm Labs Corp., a Canadian-based cannabis oil and concentrate provider, said it has launched LABS Cannabis CBD Isolate in Canada. This type of product is the first in Canada and the first in the LABS Cannabis branded product line.
According to MediPharm Labs, this product is designed for Canadians seeking a THC-free experience. 99% pure CBD crystal isolates are offered to consumers through retailers throughout Canada.
Cannabidiol or CBD is a naturally occurring cannabinoid component of cannabis. It is a commonly used medicinal marijuana chemical and does not have the toxic effects of tetrahydrocannabinol and THC.
“Commercial-produced LABS Cannabis CBD Isolate contains only trace amounts of THC (less than 0.2%), making it ideal for a wide range of wellness consumers and patients seeking the potential benefits of CBD without the intoxicating effects of THC. “Pat McCutcheon, CEO of MediPharm Labs, said.
Pure CBD Crystalline Separation is a fine white crystalline powder enriched with 99% pure CBD. All-natural cannabinoid products are made from cannabis extracts that have been refined through many steps. MediPharm Labs states that each container of LABS Cannabis CBD Isolate contains 500 mg of powdered product.
CBD crystal isolate has no intoxicating effect and is almost tasteless and odorless, so it can be taken daily and consumed by new or experienced wellness consumers in a variety of ways.
In early October, MediPharm Labs announced that German pharmaceutical company STADA Arzneimittel AG has signed an exclusive medical cannabis supply agreement with a wholly owned subsidiary of MediPharm. This partnership marks MediPharm’s entry into the global pharmaceutical industry in key European markets.
MediPharm Labs announced in September that it will enter Brazil in partnership with XLR8 Brazil, a distributor of Rio de Janeiro-based medical cannabis products. Brazil is the largest medical cannabis market in Latin America.
Contact for comments and feedback: firstname.lastname@example.org